Clinical Trial

Momelotinib During and After HCT in Myelofibrosis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-29; most recent amendment 2026-03-30.
Status change: Not Yet Recruiting → Recruiting 2026-02-10
Trial Details
NCT Number NCT07104799
Lead Sponsor Massachusetts General Hospital
Collaborators: GlaxoSmithKline
Conditions Myelofibrosis, Hematopoietic Cell Transplantation (HCT)
Enrollment 28 participants
Start Date 2026-02-23
Primary Completion 2028-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-31